137525-51-0
Most orderedBPC-157
Fifteen-residue gastric pentadecapeptide fragment studied in angiogenesis and repair models.
Typical release99.3%
From
£36.00
In stock
Tissue Repair & Regenerative
TB-500
Thymosin beta-4 · Tβ4 · TB4
Actin-sequestering 43-residue peptide studied in cell migration and repair models.
Total, ex VAT
£58.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 77591-33-4
- Molecular formula
- C212H350N56O78S
- Average mass
- 4963.4 g/mol
- Residues
- 43
- Class
- Actin-sequestering beta-thymosin
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- G-actin sequestration
- Cell migration and cytoskeletal remodelling
Overview
About TB-500
TB-500 is supplied as thymosin beta-4, a 43-residue peptide whose primary biochemical function is sequestering monomeric G-actin. By holding actin monomers out of the polymerising pool it changes the dynamics of cytoskeletal assembly, which is the mechanism underlying its effects on cell migration.
A note on naming: TB-500 is often described as a fragment of thymosin beta-4 rather than the full peptide, and the two are used interchangeably in the trade. We supply and certify the full 43-residue sequence, stated explicitly on the certificate, so there is no ambiguity about what is in the vial.
In short
- Full 43-residue thymosin beta-4 sequence, stated on the certificate
- Sequesters monomeric G-actin, altering polymerisation dynamics
- Studied in cell migration, angiogenesis and wound repair models
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Cytoskeletal dynamics
The actin-sequestering function makes it a direct tool for perturbing polymerisation without disrupting the cytoskeleton wholesale.
Cell migration
Migration and wound-closure assays are the most common application, following from the cytoskeletal mechanism.
Corneal and dermal repair
A substantial literature exists in epithelial repair models, particularly ocular surface work.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of TB-500 and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Actin sequestration
Identification of thymosin beta-4 as the principal actin-sequestering protein in many cell types.
Safer et al., Journal of Biological Chemistry, 1991
Repair and migration
Work establishing effects on cell migration and tissue repair across several model systems.
Goldstein et al., Expert Opinion on Biological Therapy, 2012
Questions
TB-500 — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Is TB-500 the same as thymosin beta-4?
- In practice, yes — the trade name is applied to the full peptide. Some sources describe TB-500 as an active fragment. We supply the full 43-residue sequence and state it on the certificate so there is no ambiguity.
- Is it difficult to handle?
- It is highly hydrophilic and dissolves easily. The main handling risk is adsorption to plastic at low concentrations; use low-binding tubes for dilute solutions.
- What purity is it released at?
- ≥ 98.0% area-percent. As a 43-residue sequence it carries more synthesis-related related substances than shorter peptides.
Same class
Others in Tissue Repair & Regenerative
89030-95-5
GHK-Cu
Copper(II) complex of the Gly-His-Lys tripeptide, studied in matrix remodelling and repair.
Typical release98.4%From
£46.00
In stock
67247-12-5
KPV
The C-terminal tripeptide of α-MSH, studied for anti-inflammatory activity without pigmentation effects.
Typical release99.0%From
£28.00
In stock
Important
TB-500 is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.